The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 04, 2022

Filed:

May. 04, 2018
Applicants:

Boris Farber, Brooklyn, NY (US);

Sof'ya Farber, Brooklyn, NY (US);

Artur Viktorovich Martynov, Kharkov, UA;

Inventors:

Boris Farber, Brooklyn, NY (US);

Sof'ya Farber, Brooklyn, NY (US);

Artur Viktorovich Martynov, Kharkov, UA;

Assignee:

Other;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/104 (2006.01); A61K 39/17 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/104 (2013.01); A61K 39/17 (2013.01); A61K 39/39 (2013.01); A61K 2039/521 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/55505 (2013.01);
Abstract

Field of application: the invention relates to veterinary medicine and, in particular, to vaccinology and pharmacy, and is intended for the prevention and treatment of infectious and other diseases of humans and animals, where low allergenic low reactogenic vaccination is used. The essence of the invention: developed vaccines with increased immunogenicity, low allergenicity and reactogenicity, containing antigen/toxin and adjuvant, wherein that they contain vaccine antigen/toxin inactivated by electromagnetic radiation in the ultraviolet and visible regions of the spectrum in the presence of a solution of photosensitizer and salts of divalent metals, and then covalently modified according to the residues of amino groups and hydroxyls groups of antigen/toxin available for modification, at least two modifying agents at the same time in terms of 0.01-10.0% of the mass concentration of the antigen/toxin protein, and as an adjuvant it contains hydrosol hydroxide ferric chloride.


Find Patent Forward Citations

Loading…